Journal profile · IMMUNOLOGY
Expert Review of Clinical Immunology
ISSN 1744-666X · Taylor and Francis Ltd. · UNITED STATES · Bimonthly · Founded 2005
Expert Review of Clinical Immunology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.03; JCR Q2 (journal website); subscription journal; APC charged, amount not published; median 118 days to acceptance (99 articles, last 24 months); community-reported acceptance: fairly easy; 109 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Expert Review of Clinical Immunology is published by Taylor and Francis Ltd. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Asthma and respiratory diseases, Systemic Lupus Erythematosus Research and Rheumatoid Arthritis Research and Therapies, together about 24% of its articles. Its main subfields are Rheumatology and Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Through recent research advances we are increasingly able to understand and address immune-mediated diseases. Biotechnology is yielding success in areas with a strong immunologic component, such as allergic asthma, rheumatoid arthritis, inflammatory bowel disease, psoriasis and multiple sclerosis. Nevertheless, the burden of immune-mediated diseases is still enormous, with direct and indirect costs associated with such conditions believed to exceed $100 billion in the USA alone. Expert Review of Clinical Immunology (ISSN 1744-666X) is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles and original papers regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology. Articles focus on the following key areas: Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines Performance and benefits of newly approved therapeutic agents New diagnostic approaches Screening and patient stratification Pharmacoeconomic studies New therapeutic indications for existing therapies Adverse effects, occurrence and reduction Prospects for medicines in late-stage trials approaching regulatory approval Novel treatment strategies Epidemiological studies Commentary and comparison of treatment guidelines Please note that the journal does not publish case reports, case series, or animal studies. Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases. The Expert Review format is unique. Each review provides a complete overview of current thinking in a key area of clinical immunology. Comprehensive coverage is augmented by: Expert Opinion - a personal view on the most effective or promising s
From the journal's Aims & Scope
Research area (LetPub): IMMUNOLOGY
Editor-in-chief Thomas ForsthuberPublisher website
Editorial board by country: 2 in mainland China (about 5%); most named United States 21, Italy 5, United Kingdom 3, Canada 3, Australia 3 (44 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Asthma and respiratory diseasesMedicine9.3%
- Systemic Lupus Erythematosus ResearchMedicine7.5%
- Rheumatoid Arthritis Research and TherapiesMedicine7.2%
- Allergic Rhinitis and SensitizationMedicine7.1%
- Psoriasis: Treatment and PathogenesisImmunology and Microbiology5.9%
- Immunodeficiency and Autoimmune DisordersImmunology and Microbiology5%
- Autoimmune and Inflammatory Disorders ResearchMedicine4.8%
- Immune Cell Function and InteractionImmunology and Microbiology4.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: yes
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPubMedEmbaseCASPublisher website
Other: Index Medicus, Journal Citation Reports®
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.03LetPub ·
- Impact factor (publisher) 2025
- 4Publisher website ·
- 5-year impact factor (publisher) 2025
- 4.1Publisher website ·
- CiteScore 2026-06
- 7.1LetPub ·
- CiteScore (publisher) 2025
- 7.1Publisher website ·
- SJR 2026-06
- 1.2LetPub ·
- SJR (publisher) 2025
- 1.2Publisher website ·
- SNIP 2026-06
- 1.19LetPub ·
- SNIP (publisher) 2025
- 1.19Publisher website ·
- h-index
- 42LetPub ·
- h-index
- 95OpenAlex ·
- i10-index
- 1,357OpenAlex ·
- 2-year mean citedness
- 3.78OpenAlex ·
- Self-citation rate
- 2.5%LetPub ·
- Share of gold OA articles
- 4.42%LetPub ·
Volume
- Articles per year
- 101LetPub ·
- Downloads per year (publisher)
- 374,000Publisher website ·
Articles by year OpenAlex count · 2,490 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 82 | 32 | 30 |
| 2025 | 109 | 21 | 341 |
| 2024 | 108 | 27 | 759 |
| 2023 | 149 | 47 | 1,741 |
| 2022 | 129 | 47 | 2,104 |
| 2021 | 120 | 40 | 2,579 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
118 daysMedian, submission to acceptance · P25–P75 90 days – 163 days
- Acceptance to online
- median 9 days (99 articles)
- Submission to online
- median 132 days
- Sample
- 99 articles with submission and acceptance dates (211 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Acceptance rate (publisher)
- 19%Publisher website ·
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 59 daysPublisher website ·
- Acceptance to publication
- 11 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Not considered
- case reports; case series; animal studies
Article types accepted8
- drug profilesWe welcome suggestions or recommendations for Guest Editorials, Meeting Reports, Reviews or Drug ProfilesLength not stated
- editorialEditorial | Published online: 22 Sep 2026Length not stated
- guest editorialsWe welcome suggestions or recommendations for Guest Editorials, Meeting Reports, Reviews or Drug ProfilesLength not stated
- meeting reportsWe welcome suggestions or recommendations for Guest Editorials, Meeting Reports, Reviews or Drug ProfilesLength not stated
- original paperspublishing rigorously peer-reviewed review articles and original papersLength not stated
- research articleResearch Article | Published online: 13 May 2025Length not stated
- reviewReview Article | Published online: 15 Sep 2026Length not stated
- review articlespublishing rigorously peer-reviewed review articles and original papersLength not stated
Policy excerpts from the journal's websiteOpen access, Peer review
- Open access Open access
Expert Review of Clinical Immunology is a hybrid open access journal that is part of the Taylor & Francis Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discov…
Source ↗Publisher website ·- Peer review
Does not publish case reports, case series, or animal studies. Model summary
Please note that the journal does not publish case reports, case series, or animal studies.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2005
- ISSN
- 1744-666X
- Latest issue on the website
- Volume 22, Issue 8 (2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Expert Review of Clinical Immunology
What CAS zone is Expert Review of Clinical Immunology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Expert Review of Clinical Immunology is in Zone 3 of Medicine, and in Zone 3 of the minor category Immunology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Expert Review of Clinical Immunology?
The latest impact factor listed by LetPub is 4.03; CiteScore 7.1, h-index 95.
How long does peer review take at Expert Review of Clinical Immunology?
Based on the dates recorded on 99 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 118 days (interquartile range 90–163 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”; the journal's website gives an acceptance rate of 19%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Expert Review of Clinical Immunology in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Medicine.
Where are the editorial board members of Expert Review of Clinical Immunology based?
Of the 44 board members whose country the journal's board page names, 2 (about 5%) are in mainland China; the countries named most often are United States (21), Italy (5) and United Kingdom (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Expert Review of Clinical Immunology?
According to LetPub and DOAJ records, Expert Review of Clinical Immunology is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, PubMed, Embase and CAS; that list has not been checked against each database.
Is Expert Review of Clinical Immunology open access, and what is the APC?
Expert Review of Clinical Immunology is a subscription journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .